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ABSTRACT
Introduction Profiles of high risk for future dementia 
are well understood and are likely to concern mostly 
those in low- income and middle- income countries and 
people at greater disadvantage in high- income countries. 
Approximately 30%–40% of dementia cases have been 
estimated to be attributed to modifiable risk factors, 
including hypertension, smoking and sedentary lifestyle. 
Tailored interventions targeting these risk factors can 
potentially prevent or delay the onset of dementia. Mobile 
health (mHealth) improves accessibility of such prevention 
strategies in hard- to- reach populations while at the same 
time tailoring such approaches. In the current study, we 
will investigate the effectiveness and implementation of a 
coach- supported mHealth intervention, targeting dementia 
risk factors, to reduce dementia risk.
Methods and analysis The prevention of dementia using 
mobile phone applications (PRODEMOS) randomised 
controlled trial will follow an effectiveness–implementation 
hybrid design, taking place in the UK and China. People are 
eligible if they are 55–75 years old, of low socioeconomic 
status (UK) or from the general population (China); 
have ≥2 dementia risk factors; and own a smartphone. 
2400 participants will be randomised to either a coach- 
supported, interactive mHealth platform, facilitating self- 
management of dementia risk factors, or a static control 
platform. The intervention and follow- up period will be 
18 months. The primary effectiveness outcome is change 
in the previously validated Cardiovascular Risk Factors, 
Ageing and Incidence of Dementia dementia risk score. 
The main secondary outcomes include improvement 
of individual risk factors and cost- effectiveness. 
Implementation outcomes include acceptability, adoption, 
feasibility and sustainability of the intervention.
Ethics and dissemination The PRODEMOS trial is 
sponsored in the UK by the University of Cambridge and 
is granted ethical approval by the London—Brighton 
and Sussex Research Ethics Committee (reference: 20/
LO/01440). In China, the trial is approved by the medical 
ethics committees of Capital Medical University, Beijing 
Tiantan Hospital, Beijing Geriatric Hospital, Chinese 
People’s Liberation Army General Hospital, Taishan Medical 
University and Xuanwu Hospital. Results will be published 
in a peer- reviewed journal.
Trial registration number ISRCTN15986016.
INTRODUCTION
With global ageing, the prevalence of 
dementia is expected to increase to over 130 
million in 2050, especially in low- income 
and middle- income countries (LMIC) and 
in people from low socioeconomic status 
(SES) background in high- income countries 
(HIC).1 2 Strategies need to be developed that 
aim to reduce the risk of dementia—many of 
which will be at community and population 
Strengths and limitations of this study
 ► The coach- supported mobile health intervention 
builds on the previously developed Healthy Ageing 
Through Internet Counselling in the Elderly electron-
ic health platform, which was shown to improve car-
diovascular risk of elderly in the Netherlands, France 
and Finland.
 ► The main strengths of the present study are testing 
the approach in populations with low socioeconomic 
status or different cultural settings and measuring 
whether sustained involvement of end users can 
be achieved, facilitating cultural adaptation of the 
application.
 ► Limitations of this study include the impossibility 
to completely blinding the participants, potentially 
leading to contamination, and the challenge to suffi-
ciently engage the hard- to- reach target population.
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level, but those that are individually based must be effec-
tive, affordable and easily implementable across various 
healthcare settings.
Up to 40% of dementia cases are estimated to be attrib-
utable to potentially modifiable risk factors,3 of which 
10%–20% are cardiovascular risk factors including hyper-
tension, midlife obesity, dyslipidaemia, diabetes, smoking 
and physical inactivity.4–6 To date, intervention studies 
aiming to reduce dementia risk by targeting one or more 
of these risk factors have shown inconsistent results.7 8 
Results from randomised controlled trials (RCT) on blood 
pressure- lowering treatment have suggested a benefi-
cial effect on dementia risk, although not consistently 
and convincingly.9–11 Since the presence of multiple risk 
factors may pose an additive or even synergistic effect on 
dementia risk,12 13 targeting several risk factors simulta-
neously may be more effective. The only study to date 
designed to address this question using dementia as 
primary outcome did not show a statistically significant 
effect after 6–8 years of intervention, although subgroup 
analysis suggested benefit for those with untreated hyper-
tension at baseline.14
A considerable challenge when designing a dementia 
prevention trial is the time lag between the optimal 
timing of the intervention and the onset of dementia. 
Using incident dementia as primary outcome requires 
large sample sizes and/or long follow- up periods to reach 
statistical power.15 16 Dementia risk scores could be used 
as a proxy, especially in trials with follow- up periods up to 
several years. Another challenge, possibly explaining the 
neutral results of intervention studies so far, is the small 
window for risk factor improvement given a background 
of high- quality cardiovascular risk management in HIC 
where these studies were performed.17 This lends further 
support for targeting people in LMIC and low- SES popu-
lations in HIC.
Digital health interventions have the potential to 
improve cardiovascular risk factors in middle age and 
beyond, especially when offered with human coaching 
(blended care).18 In the Healthy Ageing Through 
Internet Counselling in the Elderly (HATICE) trial, we 
recently demonstrated that a coach- supported internet 
intervention facilitating self- management of cardiovas-
cular risk factors can reduce older adults’ cardiovascular 
risk over a static control platform, both in high and low 
socioeconomic participant subgroups.19 Currently, digital 
health interventions are increasingly offered through 
smartphones. Smartphone penetration rates are espe-
cially high in HIC,20 also among people with low SES. In 
2018, 67% of people with the lowest SES in UK owned 
a smartphone.21 Approximately 40%–50% of the LMIC 
population is connected to mobile internet,20 22 with 
rates up to 60% in China.23 This renders mobile health 
(mHealth) a promising method for health delivery in 
underserved populations, including the improvement of 
cardiovascular risk factors.24 25
We have developed a coach- supported mHealth inter-
vention to reduce dementia risk by addressing common 
cardiovascular risk factors via lifestyle changes, building 
on the existing HATICE internet platform. Our aim is to 
assess the effectiveness and implementation of this smart-
phone intervention on dementia risk in older people at 
increased risk of dementia from a low- SES population 




Prevention of dementia using mobile phone applica-
tions (PRODEMOS) is a multinational, prospective, 
randomised, open- label blinded endpoint trial with 
18- month intervention and follow- up. The study follows 
a hybrid effectiveness–implementation design, taking a 
dual focus on assessing effectiveness and implementation 
outcomes.26 27 The Amsterdam University Medical Centre 
(Amsterdam UMC) is the coordinating centre.
Study population and recruitment
The study population will consist of community- dwelling 
older adults aged 55–75 years old, of low SES in the UK 
and of any SES in China, who have ≥2 dementia risk 
factors and own a smartphone. Low SES in the UK is 
operationalised as living in a postal code area ranked as 
equal to or less than the lowest third decile of the index of 
multiple deprivation.28 Eligibility criteria are similar for 
both countries, except for criteria for obesity, based on 
differences in national prevention guidelines29 (box 1).
Recruitment will take place in the Eastern Clin-
ical Research Network (National Institutes of Health 
Research) region of the UK and in the Beijing and 
Tai’an cities, China. In the UK, recruitment has started 
in January 2021 and will be undertaken by approximately 
10–15 general practioner (GP) practice. A random 
computer selection of participants living in the desig-
nated postal code areas meeting the age criterion and 
having ≥1 known dementia risk factor according to the 
GP registry will be approached through an information 
letter, inviting them to contact the local study centre. In 
China, participants will be recruited from seven hospitals 
through advertisements on hospital websites, targeted 
recruitment via local social media (WeChat) or direct 
approach by nurses and physicians. In China, recruit-
ment is expected to start mid-2021.
Intervention and control condition
Central to our study is the PRODEMOS platform, which 
interconnects the assessor portal, the participant app and 
the coach portal (figure 1). The assessor portal facili-
tates blinded collection of baseline and outcome assess-
ments for all participants. The intervention and control 
condition are both delivered through a smartphone app, 
which, in the case of intervention participants, allows 
communication with the coach portal. Data from the 
assessor portal, participant app and coach portal can 
be extracted through a researcher portal and stored in 
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a central database. The PRODEMOS platform was built 
in close collaboration between software developers 
and researchers from Amsterdam UMC, University of 
Cambridge, Brighton and Sussex Medical School, Capital 
Medical University in Beijing, health coaches and repre-
sentatives of the target population from both countries. 
The internet platform previously used in the HATICE 
trial served as the basis for the PRODEMOS platform.30 
In addition to the transition of the participants’ end into 
a mobile app, adjustments were made to the platform in 
repeated cycles of interaction with end users. In an iter-
ative process, experiences, needs and wishes from the 
target population and health coaches regarding the app 
and coach support, gained through interviews and focus 
groups, served as a guideline for further development.
Participants have only access to one of two versions 
of the participant app. Participants randomised to the 
intervention condition will have access to an interactive 
smartphone application in their own language (English 
in the UK and Mandarin in China). The intervention 
app facilitates coach- supported self- management of seven 
dementia risk factors, including overweight, unhealthy 
diet, insufficient physical activity, smoking, hyperten-
sion, dyslipidaemia and diabetes. Participants can set 
personal goals for lifestyle change, following the specific, 
measurable, achievable, realistic and time- bound prin-
ciple. Participants receive automated reminders to enter 
measurements (eg, number of steps and blood pressure) 
for these goals, facilitating progress monitoring. The 
intervention participants will receive support from an 
experienced lifestyle coach, who is trained in motivational 
interviewing and works according to a coach protocol 
based on current guidelines for risk factor management. 
Regular training sessions in each country will enhance 
uniformity in coaching procedures, taking cultural differ-
ences into account. During the baseline visit, after rando-
misation, the coach discusses the participant’s dementia 
risk profile, and a first lifestyle goal will be set through the 
app. After the baseline visit, all communication between 
the participant and coach will take place through the 
messaging functionality. Through the coach portal, the 
coach can view goals and measurements, send tailored 
education modules, and offer remote support to facilitate 
sustainable behaviour change.
Participants randomised to the control condition will 
have access to the control app, which is similar in appear-
ance but only contains education material, lacking inter-
active features and coach- support. During the baseline 
visit, control participants will receive concise feedback on 
their risk profile.
The PRODEMOS intervention in its current design is 
positioned as add- on to existing care.
Primary and secondary outcomes
Following a type II hybrid design, primary outcomes for 
effectiveness and implementation are equally important. 
The primary effectiveness outcome is the change in the 
Cardiovascular Risk Factors, Ageing and Incidence of 
Dementia (CAIDE) dementia risk score between baseline 
and 18- month follow- up.31 The main secondary effective-
ness outcomes include change in the individual modifiable 
components of the primary outcome, change in ten- year 
cardiovascular disease (CVD) risk, cost- effectiveness and 
certain clinical outcomes such as incidence of mild cognitive 
Box 1 Overview of inclusion and exclusion criteria
Inclusion criteria
 ► Age ≥55 years and ≤75 years old.
 ► Living in a postal code area ranked as equal to or less than the 
lowest third decile of IMD*.
 ► Good proficiency of the national language (English in UK and 
Mandarin in China).
 ► Possession of a smartphone.
 ► ≥ Two dementia risk factors:
 – Insufficient physical activity (self- reported intermediate or vigor-
ous activity of <150 min per week).
 – Active smoking (self- reported use of any sort of tobacco in any 
quantity).
 – Depression (by meeting at least one of the following criteria):
 – Current diagnosis by specialist or GP.
 – History of treatment for depression (ie, drug therapy or 
psychotherapy).
 – Manifest cardiovascular disease, as diagnosed by specialist or 
GP.
 – Diabetes mellitus (by meeting at least one of the following 
criteria):
 – Diagnosed by specialist or GP.
 – Use of insulin or other blood glucose- lowering medication.
 – Hypertension (by meeting at least one of the following criteria):
 – Diagnosed by specialist or GP.
 – Use of blood pressure- lowering medication.
 – Mean of baseline blood pressure measurements of ≥140 (sys-
tolic) or ≥90 (diastolic).
 – Obesity (by meeting at least one of the following criteria):
 – BMI ≥30 (UK) and ≥28 (China).
 – Baseline waist circumference ≥102 cm (men in UK), 90 cm 
(men in China), 88 cm (women in UK) and 85 cm (women in 
China).
 – Dyslipidaemia (by meeting at least one of the following criteria):
 – Diagnosed by specialist or GP.
 – Use of lipid- lowering medication.
 – Baseline total cholesterol ≥5.0 mmol/L*.
Exclusion criteria
 ► Manifest dementia, as diagnosed by specialist or GP.
 ► MMSE <24 (participants with ISCED level of >1) and MMSE <21 
(participants with ISCED level of 1).
 ► Any condition expected to limit 18- month follow- up, including me-
tastasised malignancy or other terminal illnesses.
 ► Smartphone illiteracy, defined as not being able to send a message 
from a smartphone.
 ► Visual impairment interfering with operation of a smartphone.
 ► Participating in another RCT on behaviour change.
 ► Present severe alcohol or illicit drug abuse.
*Applies only to participants in the UK.
BMI, Body Mass Index; GP, general practitioner; IMD, Index of Multiple 
Deprivation; ISCED, International Standard Classification of Education; MMSE, 
Mini- Mental State Examination; RCT, randomised controlled trial.
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impairment (MCI) and dementia. The operationalisation 
of all effectiveness outcomes is listed in table 1.
Implementation outcomes include acceptability, adop-
tion, appropriateness, feasibility, fidelity, coverage, sustain-
ability and costs of the implementation. User statistics, 
including data on goals set, messages sent and education 
items read, will be analysed to assess adoption and sustained 
use of the platform. In- depth interviews with participants 
and coaches will focus on user experiences, particularly with 
respect to barriers and facilitators for (sustained) platform 
use. All implementation outcomes and evaluation methods 
are shown in table 2.
Study logistics and data collection
The trial design is visualised in figure 2. All participants 
will receive one phone call and make three visits to a study 
venue during the study. Data are collected in electronic 
case report forms that are accessible through the assessor 
portal (figure 1).
Eligibility criteria that can be assessed remotely will be 
checked by a local research team member through the 
screening phone call. During the subsequent screening 
visit, informed consent (online supplemental file 1) will 
be obtained, and final eligibility will be assessed by admin-
istering the Mini- Mental State Examination; measuring 
blood pressure, Body Mass Index, waist circumference and 
total cholesterol (capillary blood sample in the UK; venous 
blood sample in China); and assessing physical activity, 
smoking behaviour and a brief medical history. Weight will 
be measured with a calibrated scale; blood pressure will be 
measured twice with a calibrated, automated blood pressure 
device. Screening visits will be performed by (GP) nurses 
and local research team members specifically trained to 
perform these measurements and will take place at the GP 
surgery or a nearby community venue. Standard operating 
procedures will be used to achieve uniform measurements 
within and between countries.
After the screening visit, all participants will fill in eight 
self- assessment questionnaires in the PRODEMOS app. 
These questionnaires will be used to assess secondary 
outcomes (ie, physical activity, quality of life, well- being, 
disability, depressive symptoms, self- management, anxiety 
and diet; table 1) and potential barriers for lifestyle 
behaviour change, which can inform coaches to tailor 
their coaching strategy. Seven of these questionnaires 
(ie, International Physical Activity Questionnaire—Short 
Form, EuroQol Five Dimensions, ICEpop CAPability 
Measure for Adults, WHO Disability Assessment Schedule 
2.0, Geriatric Depression Scale (GDS), Partners In Health 
and Hospital Anxiety and Depression Scale–Anxiety) have 
been externally validated in both Western and Chinese 
populations.32–45 Owing to obvious cultural differences, we 
decided to use two different diet questionnaires that were 
validated in the UK and Chinese population, respectively 
(Short- Form Food Frequency Questionnaire and Kadoorie 
Biobank Food Frequency Questionnaire).46 47
Figure 1 Overview of the prevention of dementia using mobile phone applications (PRODEMOS) platform and its 
functionalities. Main features of coach portal: viewing and adjusting details of goals and measurements; sending and receiving 
chat messages to and from the participants; sending education and news items. Main features of intervention app: setting and 
adjusting goals; entering measurements; sending and receiving chat messages to and from the coach; reading education and 
news items automatically pushed by platform or received from the coach; receiving periodic adverse event questionnaires and 
self- assessment questionnaires. Main features of assessor portal: blinded collection of participant data through electronic case 
report forms and questionnaires. The control application has similar connections with the assessor portal and the researcher 
portal/database, but is not connected to the coach portal.
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The baseline visit will be conducted face- to- face by 
the health coach at the GP practice or local community 
venue. During this visit, self- assessment questionnaires are 
reviewed, relevant medical history and medication use are 
recorded, and participants are randomly assigned to one 
of the treatment conditions. Only intervention partici-
pants will set a first lifestyle goal together with the coach, 
according to their dementia risk profile.
All participants will receive periodic adverse event (AE) 
questionnaires in the app, assessing incident dementia, 
MCI, CVD and diabetes. All self- reported outcomes will be 
verified with the participant’s treating physician.
After 18 months, the questionnaires and all measure-
ments performed during the screening and baseline visit 
are repeated during the final visit.
Randomisation and blinding
After completion of the baseline assessments, participants 
will be individually randomised in a 1:1 ratio, stratified by 
country, using a central, computer- generated sequence. 
Participating cohabiting partners will be allocated to the 
same study condition. Complete blinding of participants 
is not possible, owing to the nature of the intervention. 
Participants will be informed that they will be randomised 
to one of two lifestyle apps, without further details. All 
outcome assessments will be done by an independent 
assessor unaware of treatment allocation.
Safety and privacy
Due to the nature of the intervention, serious AEs are 
unlikely to occur, and we consider the intervention low 
risk. A data safety and monitoring board is not installed.
Some precautions are taken to optimise participant 
safety. First, regardless of their study allocation, partici-
pants will be referred to their GP or treating physician 
if deemed necessary based on their baseline or outcome 
parameters and local guidelines. Second, AEs will be 
monitored through three 6 monthly questionnaires, 
for which participants will receive notifications on their 
smartphone and reminders through email (UK) or SMS 
(China). If the participant is not able to fill in the ques-
tionnaire, an informant can be contacted. A blinded 
researcher will, with explicit permission gained through 
the informed consent procedure, cross- check all reported 
AEs by consulting the participant’s GP or treating 
physician. Third, the PRODEMOS platform is built in 
accordance with the highest security requirements in 
healthcare. It complies with NEN 7510, the Health Insur-
ance Portability and Accountability Act, ISO 133485 and 
General Data Protection Regulation.
Protocol adjustments due to COVID-19 pandemic
As a result of the COVID-19 pandemic and related local 
research restrictions, certain adjustments have been made 
to the original study protocol as published on the Inter-
national Standard Randomised Controlled Trial Number 
Register (ISRCTN). First, recruitment was planned to 
start in early 2020 but had to be suspended until January 
2021. Second, as it is difficult to predict the development 
of the pandemic and associated restrictions, we have 
slightly amended the study protocol to allow for flexible 
Table 1 Effectiveness outcomes
Primary outcome Points
CAIDE Score (range: 0–15), which is composed of and calculated from the 
following:
Age   
  <47 years 0
  47–53 3
  >53 4
Education   
  ≥10 years 0
  7–9 years 2
  <7 years 3
Gender   
  Female 0
  Male 1
Systolic blood pressure   
  ≤140 mm Hg 0
  >140 mm Hg 2
BMI   
  ≤30 kg/m2 0
  >30 kg/m2 2
Total cholesterol   
  ≤6.5 mmol/L 0
  >6.5 mmol/L 2
Physical activity*   
  Yes 0
  No 1
Secondary outcomes   
Individual modifiable components of the 
CAIDE score†
Estimated 10- year cardiovascular 
risk
Number of uncontrolled risk factors LIBRA dementia risk score
Active smoking Number of hospital admissions
Medication adherence Diet‡
Number of drugs Disability§
Incident dementia¶ Anxiety**
Incident MCI¶ Self- management††
Incident cardiovascular disease¶,§§ Depressive symptoms‡‡
Incident diabetes¶ Quality of life¶¶
All- cause mortality Cost- effectiveness
*Assessed according to WHO standard for physical activity of at least 150 min per 
week.
†Physical activity assessed with the International Physical Activity Questionnaire—
Short Form.
‡Assessed with Short- Form Food Frequency Questionnaire (UK) and China Kadoorie 
Biobank Food Frequency Questionnaire (China).
§Assessed with the WHO Disability Assessment Schedule.
¶Self- reported and cross- checked with general practitioner file.
**Assessed with the Hospital Anxiety and Depression Scale—Anxiety.
††Assessed with the Partners In Health.
‡‡Assessed with the Geriatric Depression Scale.
§§Defined as myocardial infarction or stroke.
¶¶Assessed with the ICEpop CAPability Measure for Adults and EuroQol Five 
Dimensions Three Levels.
BMI, Body Mass Index; CAIDE, Cardiovascular Risk Factors, Ageing and Incidence of 
Dementia; LIBRA, Lifestyle for Brain Health; MCI, mild cognitive impairment.
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measurement procedures at baseline that can be opera-
tionalised in either one or two face- to- face visits and for a 
flexible intervention duration of 12–18 months. However, 
we will strive for a follow- up period of 18 months in as 
many participants as possible.
Patient and public involvement
We have received valuable input into the design of the 
study and mHealth platform from multiple interactive 
sessions with GPs, health coaches, researchers, repre-
sentatives of people living with dementia, community 
leaders and policy makers. Needs and views regarding the 
intervention were assessed through interviews and focus 
groups with potential end users in both countries. All 
patient- facing material used in the UK has been reviewed 
by potential end users. Qualitative evaluations of the 
pilot study with research staff, coaches and patient partic-




The CAIDE Score will be used as primary effective-
ness outcome. We decided to use a difference of 0.186 
points on the CAIDE Score between the average of 
both study groups as a minimum target threshold, 
because this difference was observed in the Prevention 
of Dementia by Intensive Vascular Care trial after 2 
years (p=0.005; intervention group=−0.290±1.47 SD and 
control group=−0.104±1.36 SD). Attrition after 2 years of 
follow- up was 21% in this study.14 With 80% power, a 0.05 
two- sided significance level, accounting for 21% attrition, 
and a mean difference in change in CAIDE of 0.186, the 
required sample size is estimated to be 2319 participants. 
To allow for unexpected factors, we raised this to 2400.
Data analysis
The effect on the CAIDE Score will be analysed using 
linear mixed- effect models according to the intention- 
to- treat principle, taking clustering within partner pairs 
and country into account by testing best fit for random 
intercept and/or slope. If needed, we will adjust for base-
line imbalances and take clustering of the intervention 
within centre and/or coach into account. No imputation 
of the CAIDE Score will be done for the primary analysis. 
In sensitivity analyses, we will use multiple imputation 
to assess the impact of missing items needed to calcu-
late the CAIDE Score, provided there are no indications 
that the variables are missing not at random, and a per- 
protocol analysis for those adherent to the intervention 
will be performed. Moreover, we will explore the inter-
action of intervention duration with the effect of the 
invention by adding an interaction term (intervention 
duration*randomisation group) to the main model. This 
will give insight into the potential additional intervention 
Table 2 Summary of implementation research methods and outcomes
Method Outcome Measurement Population*
Timing of 
assessment
Quantitative Coverage (Non)Response rates, comparison 
characteristics of participants with eligible 
population
Potential target population At baseline
Adoption Utilisation, usage, and uptake Intervention participants, 
coaches
After 2 weeks
Appropriateness Short questionnaire of perceived fit or 




After 3 months and at 
study end




After 3 months and at 
study end
Sustainability Adherence, dropout Intervention participants, 
dropouts†
Throughout the study
Cost Implementation costs N.A. N.A.
Qualitative Feasibility The extent to which the mHealth intervention 




After 3 months and at 
study end




After 3 months and at 
study end
Acceptability Agreeability, user- friendliness, credibility Intervention participants, 
dropouts,† coaches
After 3 months and at 
study end
Fidelity Degree to which the mHealth application 
is implemented compared with the original 
protocol
N.A. After the study
*For all analyses, a Chinese and UK population will be involved.
†Study dropouts will be asked to participate in a short exit interview.
mHealth, mobile health.
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effect in participants with a follow- up time of less than 18 
months.
Subgroup analyses will be performed for country, sex, 
age group, having a history of CVD, number of risk factors, 
willingness to change lifestyle (assessed with one ques-
tion during the baseline visit), participation with(out) a 
participating partner, having the same coach during the 
full length of the study and the number of goals set. For 
all these factors, interaction terms will be included to test 
for between- subgroup differences in intervention effects.
The effect on individual modifiable components of the 
CAIDE Score and 10- year CVD Risk Scores will be analysed 
using linear mixed- effect models according to the intention- 
to- treat principle, taking clustering within partner pairs 
and country into account. Self- assessment scales, which are 
mostly ordinal, will be regarded as linear scales if there are 
at least four categories and the ‘distance’ between the cate-
gories can be regarded equal. Poisson regression or zero- 
inflated models may be applied to distributions resembling 
count or zero- inflated data. The choice of the final model 
will be a compromise between optimal fit and interpret-
ability of the results for a general clinical public.
Prevalence ratios will be used for self- assessment instru-
ments with defined cut- offs for the presence or absence 
of a condition, for example, ‘depressive symptoms’ for a 
GDS >5. For (clinical) dichotomous outcomes, such as 
incident CVD, dementia or mortality, Cox proportional 
hazard models will be used with time using baseline as 
timescale. A sensitivity analysis will be performed using 
age as timescale.
Figure 2 Trial design. AE, adverse event; ISCED, International Standard Classification of Education; MMSE, Mini- Mental State 
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The full analysis plan, including the health economic 
analysis plan entailing the cost–consequence analysis of 
the within- trial results, the cost- effectiveness analyses and 
the cost–utility analysis and hypotheses for the subgroup 
analyses, is published on the ISRCTN website: http://
www. isrctn. com/ ISRCTN15986016.
Pilot study
Between December 2019 and March 2020, a 6- week pilot 
study was conducted in the Brighton and Sussex area, 
the UK. Since the main aim was to test study logistics and 
functionality of the intervention app, participants were 
randomised in a 3:1 (intervention/control) ratio. An invi-
tation letter was sent to 600 potentially eligible patients 
from two GPs. The response rate was 14.8% (n=89), of 
whom 21 participants (3.5%) could be included. The 
main reasons for exclusion were not living in the desig-
nated postal code area and having <2 dementia risk 
factors. Participants had a median age of 69 years old, and 
12 (57%) were men. Fifteen participants were allocated 
to the intervention group and six to the control group.
During the pilot study, 10 of 15 intervention partici-
pants set at least one goal (range: 1–8 goals). Goals were 
set in five domains, including physical activity, healthy 
diet, body weight, blood pressure and cholesterol. Six 
of ten participants entered goal- related measurements 
(range: 2–243 measurements). All intervention partici-
pants used the chat functionality to consult the coach. In 
total, 278 messages were sent back and forth, that is, on 
average three messages per intervention participant per 
week.
The pilot study was evaluated through qualitative 
sessions with the participants and coaches. The main 
adjustments based on the participants’ feedback included 
improvements to the chat functionality (allowing attach-
ments and larger font size), simplification of the func-
tionality to enter and view measurements, setting the 
first goal together with the coach and more detailed 
instructions for app use through an instruction video and 
written manual. Based on feedback from the coaches, we 
improved the functionalities for population management 
in the coach portal, including an input screen to make 
notes about individual participants and a functionality to 
send education material to (groups of) participants.
A similar pilot study will be conducted in China, to 
test platform functionality and study logistics in all seven 
participating trial centres.
DISCUSSION
In the PRODEMOS study, we will investigate the imple-
mentation of a self- management mHealth intervention 
with remote coaching and its effect on dementia risk over 
18 months. We will target people aged 55–75 years old 
with elevated dementia risk of low SES in the UK and of 
any SES in the Beijing and Tai’an cities in China, as these 
populations are usually not reached by preventive strate-
gies and may benefit the most. User data and qualitative 
analysis of our pilot study suggest that our mHealth appli-
cation, after further adaptations to improve attractiveness 
and usability, is now ready to be studied in older adults 
who are interested in participating in a study on lifestyle 
change to lower their overall dementia risk.
The HATICE trial has shown that a coach- supported 
internet platform can improve cardiovascular risk factors 
in European elderly. Although we build on these expe-
riences, the modality (ie, app instead of internet plat-
form) and target population are different. The resulting 
uncertainty that there would be a similar benefit of our 
intervention renders the use of a hybrid effectiveness–
implementation design highly suitable.27
Strengths
Chronic disease risk is largely affected by socioeconomic 
factors, including psychological, cultural and economic 
characteristics, requiring preventive strategies that take 
these aspects into account.48 In PRODEMOS, we aim to 
support individuals by offering intensive human support 
through the app and by aligning the intervention with 
the healthcare system. In order to eventually embed a 
complex prevention intervention into primary health-
care, it is crucial to involve and consult all stakeholders, 
such as GPs, practice nurses, and end users.49 In the 
current hybrid effectiveness–implementation study, we 
take some first steps to explore the possibilities and chal-
lenges for embedding the intervention in existing health-
care. This study will provide concrete evidence of the 
scale of the change that might be achieved for individuals 
at risk, whether and how this approach is taken up within 
diverse populations.
The PRODEMOS study is designed as one trial, 
recruiting participants in two different countries, 
increasing the external validity of the results. Overall, 
both countries will follow the same research protocol and 
highly similar standard operating procedures and will 
investigate similar interventions. Through semistructured 
interviews among the elderly in Beijing and the UK, we 
learnt that needs and wishes regarding lifestyle behaviour 
change through mHealth are largely similar (manu-
scripts currently being drafted). Therefore, the Chinese 
and UK intervention will share the same functionalities 
and coaching procedures. Given obvious cultural- related 
and healthcare- related differences, certain aspects of the 
study logistics, lifestyle support and layout of the app had 
to be culturally adjusted. In a preplanned subgroup anal-
ysis, we will assess both effectiveness and implementation 
outcomes for both countries separately.
Limitations
The study may yield some limitations. First, the optimal 
age range for trials on dementia risk reduction is 
unknown.15 There is a trade- off between potentially more 
effective treatments in midlife and the chance to detect 
treatment effects on cognitive outcomes in late life.4 As 
in the current study, we are assessing both a dementia 
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risk score and clinical outcomes; we have taken a prag-
matic approach, targeting individuals aged 55–75 years 
old15.
Second, change in CAIDE dementia risk score is not 
easily translated into incidence of dementia. However, 
although not specifically designed as RCT outcome 
measure, the CAIDE Score can detect change over time.50
A third potential limitation is that, owing to the nature 
of the intervention, blinding of the participants is only 
partly possible. A certain degree of contamination might 
occur, especially in communities that live closely together. 
The study logistics and intervention are designed in 
such a way as to limit contact between participants after 
randomisation.
Finally, the results of the baseline measurements will be 
revealed to all participants, potentially leading to treat-
ment effects in both study conditions. Also, behaviour of 
participants and their treating physicians may change in 
both study conditions as a reaction to the awareness of 
being part of the study (Hawthorne effect). Both mech-
anisms will perhaps mask (part of) the ‘true’ contrast 
in dementia risk between the intervention and control 
condition.
For the planned health economic analyses, we will 
rely on economic modelling, based on the interme-
diate outcomes reflecting risk of dementia and CVD and 
assumptions on their causality with the clinical endpoints 
dementia and CVD, because the study is not designed nor 
powered to detect an effect on these clinical endpoints.
The high prevalence of dementia, lower provision of 
high- quality cardiovascular preventive care in LMIC 
and lower uptake of such programmes in Western low- 
SES populations require affordable and straightforward 
preventive strategies. If proven effective and imple-
mentable, our pragmatic smartphone intervention facil-
itates widespread use and reduction of dementia risk for 
hard- to- reach populations across the globe.
ETHICS AND DISSEMINATION
The PRODEMOS trial is sponsored in the UK by the 
University of Cambridge and is granted ethical approval 
by the London–Brighton and Sussex Research Ethics 
Committee (reference: 20/LO/01440). In China, the 
trial is approved by the medical ethics committees of 
Capital Medical University, Beijing Tiantan Hospital, 
Beijing Geriatric Hospital, Chinese People’s Liberation 
Army General Hospital, Taishan Medical University and 
Xuanwu Hospital. Data will be exported in a pseudony-
mised format according to prevailing guidelines on good 
clinical practice in both countries. Only anonymised data 
will be exchanged between the UK, China and the Neth-
erlands. The exported data will be stored centrally on a 
protected server in the Netherlands, which is compat-
ible with the highest standards of data management in 
medical research. Results will be published in a peer- 
reviewed journal.
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